Starpharma shares soar on back of AstraZeneca collaboration; Jim Allison wins Lasker award;

@FierceBiotech: Purdue puts up $213M for a novel pain drug from VM Pharma. Report | Follow @FierceBiotech

@JohnCFierce: AstraZeneca nabs priority review voucher as Wellstat bags FDA OK. Report | Follow @JohnCFierce

@DamianFierce: NYT editorial takes a weird, non-systemic middle ground on PCSK9 pricing. Article | Follow @DamianFierce

> Shares of Melbourne, Australia-based Starpharma (ASX: SPL, OTCQX: SPHRY) soared today after the company announced a collaboration with AstraZeneca ($AZN), putting their drug delivery tech to work for the pharma giant. Starpharma grabbed a $2 million upfront with milestones ranging up to $124 million for the first product, with more to come if it extends to additional programs. Release

> Jim Allison, an immuno-oncology expert now at MD Anderson, won the prestigious Lasker-DeBakey Clinical Medical Research Award. Report

> Tampa, FL-based Oxis Biotech inked a license agreement to further develop and commercialize DT2219ARL, a novel therapy for B cell cancers, leukemias and lymphomas. Release

Medical Device News

@FierceMedDev: ICYMI from FierceDiagnostics: Focus Diagnostics gets FDA blessing to expand label for herpes test. Story | Follow @FierceMedDev

@StacyALawrence: ICYMI Friday: Allergan to grab AqueSys for $300M+ to add minimally invasive glaucoma microshunt. Article | Follow @StacyALawrence

@EmilyWFierce: ICYMI from FiercePharma: Novartis snags EU approval for multiple myeloma med Farydak. Report | Follow @EmilyWFierce

> GSK-backed SetPoint raises $15M to advance anti-inflammatory, neuromodulation device. Article

> Novartis CEO: Smart contact lenses 'progressing well' with first human trials set for 2016. Report

Pharma News

@FiercePharma: Japan's Chugai notes U.S. FDA breakthrough designation for ACE910. More from FiercePharmaAsia  | Follow @FiercePharma

@CarlyHFierce: ICYMI Friday: AstraZeneca scores FDA nod for long-term Brilinta use. Article | Follow @CarlyHFierce

> Perrigo's fate is in shareholders' hands, Mylan chairman says. Or is it? Story

> Roche CEO lashes out at U.K.'s 'stupid' move to stop paying for a dozen-plus cancer meds. More

> Study: Pfizer's Chantix does not increase risk of depression, heart attack in smokers. Report

Animal Health News

> Report: Bees self-medicate to protect against parasites. More

> Nexvet doubles down on R&D spending as net loss widens. Report

> Veterinarian's op-ed piece says antibiotic ban taking tools away from vets. Article

> New mobile app allows virtual veterinary consultations. Item

> UC Davis veterinarian pushes 'One Health' system for scientific literature. Story

Biotech IT News

> NIH commits $49M to fuel fusion of genomic data and EHRs. News

> Labfolder taps investors for cash to develop ELN system. Report

> Thermo Fisher rolls out Ion S5 sequencer in play for clinical trial sector. Story

> CD Genomics adds HiSeq X Ten to suite of tools for sequencing services. Item

> Google hooks up with Sanofi to continue diabetes drive. Article

Drug Delivery News

> Gene therapy approach for T1 diabetes could alter immune system to boost insulin. Report

> Sanofi looking to expand U.K. plant that does contract manufacturing of inhaled meds. Story

> Columbia U. team delivers small liquid drug doses to the lungs for targeted treatment. More

> Study finds e-cigarettes are being used to vaporize pot. Item

> Generic alternative to Novartis' transdermal patch for Alzheimer's hits the market. Article

Pharma Manufacturing News

> Recipharm to buy Alcon plant as part of manufacturing agreement. News

> GSK runs into supply issues after China plant damaged by nearby explosion. More

> MSF warns that Sanofi leaving antivenom market will lead to treatment crisis. Report

> Cipla gets first U.S. manufacturing plant with InvaGen buy. Article

> U.K. generics maker starts plant in Alabama. Story

Pharma Asia News

> Japan's PAFSC gives nods to Takeda's glatiramer, MSD's omarigliptin. News

> Samsung Bioepis wins South Korea nod for SB4, etanercept biosimilar. Story

> India denies Pfizer application for additional Xeljanz patents. More

> Japan's Chugai notes U.S. FDA breakthrough designation for ACE910. Item

> Hutchison MediPharma's fruquintinib notches a second with proof-of-concept result. Article

Suggested Articles

The ambitious target is enabled by an AI discovery platform that Healx thinks gives it a scalability that has more in common with tech than biotech.

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.